Literature DB >> 6227665

Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses.

A Landay, G L Gartland, L T Clement.   

Abstract

Two new monoclonal antibodies (termed 2D2 and D12) have been used to identify and to analyze phenotypically distinct subpopulations of human T cells. The 2D2 antibody recognized an antigenic determinant closely related, if not identical, to that reactive with the anti-Leu-2 monoclonal antibody. The D12 antibody reacted with a variety of cell types, which included a subpopulation of Leu-2+ (2D2+) T cells. These antibodies were used to isolate four phenotypically distinct T cell populations by sequential cell sorter techniques. Functional analyses demonstrated that the 2D2+D12+ subset was unique in its ability to suppress the antigen-induced proliferation of T cells. These cells also suppressed the proliferative responses of other T cell subsets stimulated with mitogens. Pretreatment of 2D2+D12+ T cells with mitomycin C before culture abrogated the suppressor cell activity of these cells. We propose that the cells within the Leu-2+ cytotoxic/suppressor T cell subpopulation that suppress T cell proliferation are phenotypically distinct and express the 2D2+D12+ membrane antigenic phenotype.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6227665

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer.

Authors:  M Takahashi; S Fujimoto; M Takai; K Ohno; F Endoh; Y Masuda; Y Masuda; G Obata
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

2.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

3.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

4.  Most CD8+ cells in skin lesions of CD3+ CD4+ mycosis fungoides are CD3+ T cells that lack CD11b, CD16, CD56, CD57, and human Hanukah factor mRNA.

Authors:  G S Wood; C Dubiel; C Mueller; E A Abel; R T Hoppe; A Edinger; I Weissman; R A Warnke
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

5.  Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.

Authors:  F A Karlsson; T H Tötterman
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

6.  Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.

Authors:  R Gustafsson; T H Tötterman; L Klareskog; R Hällgren
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

7.  Dual labelling of circulating CD8 cells in patients with multiple sclerosis.

Authors:  P J Hughes; P F Kirk; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

Review 8.  T-cell clones and T-cell receptors.

Authors:  F W Fitch
Journal:  Microbiol Rev       Date:  1986-03

9.  One half of the CD11b+ human peripheral blood T lymphocytes coexpresses the S-100 protein.

Authors:  C Ferrari; P Sansoni; G Rowden; G C Manara; C Torresani; G De Panfilis
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

10.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.